Table 4.
Associations between individual HLA-DRB1 haplotype and achieving good/moderate EULAR response, in overall RA, as well as in ACPA-positive RA and ACPA-negative RA
| Haplotype | Prevalence (%) | Overall RA | ACPA-positive RA | ACPA-negative RA |
|---|---|---|---|---|
| PRAA | 10.2 | Reference | Reference | Reference |
| DFRE | 1.7 | 1.60 (0.51–5.03) | 1.60 (0.48–5.34) | NA |
| GYRQ | 4.8 | 0.59 (0.29–1.19) | 0.64 (0.28–1.47) | 0.18 (0.03–1.28) |
| LFEA | 0.4 | 0.23 (0.04–1.55) | NA | NA |
| LFRA | 14.9 | 0.89 (0.51–1.56) | 0.93 (0.49–1.79) | 0.33 (0.06–1.88) |
| PRRA | 0.8 | 0.89 (0.20–3.94) | 2.15 (0.23–20.28) | NA |
| SGRA | 1.7 | 0.72 (0.26–1.96) | 0.81 (0.27–2.47) | 0.28 (0.01–5.30) |
| SGRL | 2.9 | 1.00 (0.41–2.43) | 1.23 (0.37–4.10) | 0.14 (0.02–0.95) |
| SSEA | 5.4 | 0.92 (0.45–1.86) | 1.31 (0.53–3.28) | 0.12 (0.02–0.73) |
| SSKA | 0.7 | 2.49 (0.29–21.30) | NA | 0.12 (0.01–2.59) |
| SSKR | 9.3 | 0.99 (0.47–2.10) | 1.23 (0.51–2.99) | 0.04 (0.00–0.39) |
| SSRA | 3.6 | 1.98 (0.78–5.00) | 2.43 (0.81–7.32) | 0.55 (0.06–5.03) |
| SSRE | 1.1 | 1.59 (0.32–7.82) | 2.58 (0.30–22.14) | 0.10 (0.00–2.41) |
| VFRA | 2.1 | 0.52 (0.21–1.24) | 0.60 (0.22–1.63) | 0.17 (0.01–2.84) |
| VHEA | 0.3 | 1.14 (0.11–12.24) | 1.58 (0.14–17.89) | NA |
| VHKA | 27.0 | 0.78 (0.46–1.32) | 1.08 (0.59–1.97) | 0.16 (0.03–0.93) |
| VHRA | 11.9 | 1.10 (0.62–1.97) | 1.20 (0.62–2.33) | 0.93 (0.11–8.00) |
| VHRE | 1.3 | 1.03 (0.31–3.43) | 2.11 (0.43–10.35) | 0.03 (0.00–0.55) |
| PAA | 10.2 | Reference | Reference | Reference |
| DRE | 1.7 | 1.59 (0.51–5.01) | 1.56 (0.47–5.20) | NA |
| GRQ | 4.8 | 0.59 (0.29–1.19) | 0.63 (0.27–1.45) | 0.19 (0.03–1.33) |
| LEA | 0.4 | 0.23 (0.03–1.50) | NA | NA |
| LRA | 14.9 | 0.89 (0.51–1.55) | 0.93 (0.49–1.77) | 0.34 (0.06–1.92) |
| PRA | 0.8 | 0.90 (0.20–3.98) | 2.11 (0.22–19.84) | NA |
| SEA | 5.4 | 0.95 (0.47–1.91) | 1.36 (0.55–3.39) | 0.13 (0.02–0.75) |
| SKA | 0.7 | 2.62 (0.31–22.35) | NA | 0.13 (0.01–2.73) |
| SKR | 9.3 | 1.01 (0.48–2.13) | 1.26 (0.52–3.05) | 0.05 (0.00–0.43) |
| SRA | 5.3 | 1.34 (0.64–2.79) | 1.51 (0.65–3.52) | 0.48 (0.06–3.63) |
| SRE | 1.1 | 1.52 (0.31–7.42) | 2.47 (0.29–21.15) | 0.10 (0.00–2.51) |
| SRL | 2.9 | 0.94 (0.39–2.27) | 1.20 (0.36–3.98) | 0.13 (0.02–0.92) |
| VEA | 0.3 | 1.15 (0.11–12.39) | 1.56 (0.14–17.60) | NA |
| VKA | 27.0 | 0.77 (0.46–1.30) | 1.06 (0.58–1.94) | 0.15 (0.03–0.91) |
| VRA | 14.0 | 0.95 (0.55–1.64) | 1.04 (0.55–1.94) | 0.64 (0.09–4.31) |
| VRE | 1.3 | 1.03 (0.31–3.44) | 2.08 (0.42–10.27) | 0.04 (0.00–0.66) |
ACPA anti-citrullinated protein/peptide antibodies, RA rheumatoid arthritis, EULAR European League Against Rheumatism